ERLEADA ™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news